Treatment for patients with HR + /HER2 − aBC/mBC had been unchanged for almost two decades prior to the approval of palbociclib, a first-in-class oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitor approved in 2015. Here, ERBB2 is linked to aneurysmal bone cyst.